ClinicalTrials.gg

Meningitis, Meningococcal clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 125 studies for Meningitis, Meningococcal across more than 10 countries. 10 are recruiting or about to start. 111 of them are mainly about Meningitis, Meningococcal (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21.

Status

Completed
97
Status unknown
9
Not yet recruiting
5
Recruiting
5
Active, not recruiting
5
Terminated
3

Phase

Phase 3
54
Phase 2
35
Phase 4
16
Phase 1
13

Where

United States
36
China
19
Germany
11
Spain
10
United Kingdom
9
Italy
8

Who develops what

Add Meningitis, Meningococcal to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 2 companies, 3 with this as their studies’ main aim; 2 with a live phase 3 study; 4 primary completions in the next 12 months. Compare CanSino Biologics and Sinovac Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ACYW135Recent, limited
Evidence
  • NCT06337071 · aimei vacin biopharm zhejiang co ltd · Phase 2 · live · comparator · “ACYW135 Meningococcal Polysaccharide Vaccine” · registered Mar 2024
—11 study
Meningococcal VaccinesRecent, limited
Evidence
  • NCT06131554 · CanSino Biologics Inc. · Phase 3 · comparator · “Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine” · registered Nov 2023
  • NCT04707391 · GlaxoSmithKline · Phase 3 · comparator · “MenACWY vaccine” · registered Jan 2021
  • NCT03964012 · Serum Institute of India Pvt. Ltd. · Phase 3 · comparator · “Menactra” · registered May 2019
  • NCT03587207 · GlaxoSmithKline · Phase 2 · comparator · “MenACWY (Menveo) vaccine” · registered Jun 2018
  • NCT03547271 · Sanofi · Phase 3 · comparator · “Meningococcal group A, C, W-135, and Y conjugate vaccine” · registered May 2018
—11 study
13-valent pneumococcal vaccineEarlier onlyPhase 4 trial recorded
Evidence
  • NCT03621670 · GlaxoSmithKline · Phase 3 · background · “Prevnar13” · registered Jul 2018
  • NCT03537508 · Sanofi · Phase 3 · background · “Pneumococcal 13-valent conjugate vaccine” · registered May 2018
Pfizer73% of its industry studies00 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
experimental vaccinePhase 4 trial recorded☆ Track4 live phase-3 studies: NCT07505823, NCT07505810, NCT07505888Sinovac Biotech Co., Ltd
MCV4Phase 4 trial recorded☆ Track1 live phase-3 study: NCT06226714CanSino Biologics Inc.

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.experimental vaccine · Sinovac Biotech Co., Ltd · Phase 3 main aimNCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years — primary endpoint: Seroconversion rates (%) of Nm antibodies for serogroups A, C, Y, W135 · 660 enrolled
  • Jan 2027 est.experimental vaccine · Sinovac Biotech Co., Ltd · Phase 3 main aimNCT07505836 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months — primary endpoint: seroconversion rates (%) of Nm antibodies for serogroups A, C, Y, W135 · 1,040 enrolled
  • Apr 2027 est.experimental vaccine · Sinovac Biotech Co., Ltd · Phase 3 main aimNCT07505823 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months — primary endpoint: seroconversion rates (%) of Nm antibodies for serogroups A, C, Y, W135 · 1,040 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Meningitis, Meningococcal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

6studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, 0 (0%) set no upper age limit and 5 (100%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (100%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
100 (0%)0 (0%)
181 (20%)1 (20%)
301 (20%)1 (20%)
401 (20%)1 (20%)
501 (20%)1 (20%)
650 (0%)0 (0%)
750 (0%)0 (0%)
850 (0%)0 (0%)

Across all 125 studies, recruiting or not: 91% stop at 75 or younger and 91% at 65; 77% take children; 1% are for women only and 0% for men only; 93% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Meningitis, Meningococcal studies take

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 37 mo6–20 · 25 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 125. Browse all 125 → or search them.